Abivax
ABVX
36 hedge funds and large institutions have $334M invested in Abivax in 2024 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
44% more capital invested
Capital invested by funds: $232M → $334M (+$102M)
20% more funds holding
Funds holding: 30 → 36 (+6)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
2.65% more ownership
Funds ownership: 34.51% → 37.15% (+2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.1M |
| 2 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$8.03M |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$4.88M |
| 4 |
VA
VR Adviser
New York
|
+$4.48M |
| 5 |
Walleye Capital
New York
|
+$2.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.38M |
| 2 |
Blackstone Inc
New York
|
-$3.24M |
| 3 |
AA
AlphaCentric Advisors
San Juan,
Puerto Rico
|
-$2.86M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$2.34M |
| 5 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$1.83M |
ABVX Hedge Fund Activity: Q1 2024 in Review
36 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Abivax (ABVX) for Q1 2024, worth a combined $334M — up 44% from $232M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ABVX positions and 6 closed out — a net gain of 6 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Great Point Partners, adding an estimated $12.1M. The largest seller was Morgan Stanley, cutting an estimated $3.38M.
- 36 institutional investors held Abivax (ABVX) as of Q1 2024, up from 30 in Q4 2023.
- Funds reported $334M of Abivax stock for Q1 2024, up 44% quarter-over-quarter.
- 12 funds opened new Abivax positions in Q1 2024 and 6 closed out, a net change of +6 holders.
- The largest Abivax buyer in Q1 2024 was Great Point Partners, an estimated $12.1M added.
- The largest Abivax seller in Q1 2024 was Morgan Stanley, an estimated $3.38M sold.
Based on aggregated 13F filings for Q1 2024.